1. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am College Cardiol. 2020;76(25):2982-3021. [
DOI:10.1016/j.jacc.2020.11.010] [
PMID] [
]
2. Warraich HJ, Hernandez AF, Allen LA. How medicine has changed the end of life for patients with cardiovascular disease. J Am College Cardiol. 2017;70(10):1276-89. [
DOI:10.1016/j.jacc.2017.07.735] [
PMID]
3. Heo S, Lennie TA, Okoli C, Moser DK. Quality of life in patients with heart failure: ask the patients. Heart Lung. 2009;38(2):100-8. [
DOI:10.1016/j.hrtlng.2008.04.002] [
PMID] [
]
4. Pihl E, Cider Å, Strömberg A, Fridlund B, Mårtensson J. Exercise in elderly patients with chronic heart failure in primary care: effects on physical capacity and health-related quality of life. Europ J Cardiovasc Nurs. 2011;10(3):150-8. [
DOI:10.1016/j.ejcnurse.2011.03.002] [
PMID]
5. Pitt B, Pedro Ferreira J, Zannad F. Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives. Europ Heart J Cardiovasc Pharmacother. 2017;3(1):48-57. [
DOI:10.1093/ehjcvp/pvw016] [
PMID]
6. Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nature Rev Cardiol. 2017;14(1):30-8. [
DOI:10.1038/nrcardio.2016.163] [
PMID] [
]
7. Miller AB. Aldosterone antagonism in heart failure. Vasc Health Risk Manage. 2007;3(5):605-9.
8. Vizzardi E, Regazzoni V, Caretta G, E, et al. Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives. Int J Cardiol Heart Vessels. 2014;3:6-14. [
DOI:10.1016/j.ijchv.2014.03.005] [
PMID] [
]
9. Ziaeian B, Fonarow GC. The prevention of hospital readmissions in heart failure. Prog cardiovasc Dis. 2016;58(4):379-85. [
DOI:10.1016/j.pcad.2015.09.004] [
PMID] [
]
10. Kawano H, Node K. Medical agents acting on the renin-angiotensin-aldosterone axis for the treatment of heart failure. Hyperten Res. 2010;33(3):192-3. [
DOI:10.1038/hr.2009.232] [
PMID]
11. Pitt B, Zannad F, Remme WJ, Investigators RAES. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med.1999;341(10):709-17 [
DOI:10.1056/NEJM199909023411001] [
PMID]
12. Cicoira M, Zanolla L, Rossi A, et al. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am College Cardiol. 2002;40(2):304-10. [
DOI:10.1016/S0735-1097(02)01965-4] [
PMID]
13. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Cardiac Fail. 2004;10(4):297-303. [
DOI:10.1016/j.cardfail.2003.10.012] [
PMID]
14. Savarese G, Stolfo D, Sinagra G, Lund LH. Heart failure with mid-range or mildly reduced ejection fraction. Nature Rev Cardiol. 2022;19(2):100-16. [
DOI:10.1038/s41569-021-00605-5] [
PMID] [
]
15. Albert J, Lezius S, Störk S, et al. Trajectories of left ventricular ejection fraction after acute decompensation for systolic heart failure: concomitant echocardiographic and systemic changes, predictors, and impact on clinical outcomes. J Am Heart Assoc. 2021;10(3):e017822. [
DOI:10.1161/JAHA.120.017822] [
PMID] [
]
16. Rajaei E, Isfahani NP, Akiash N, Mohammadi M, Mowla K. Evaluation of the left ventricular function in patients with scleroderma with normal pulmonary artery pressure using myocardial strain analysis: A cross-sectional study. Int Cardiovasc Res J. 2022;16(4).
17. Arazi T, Aliasgharpour M, Mohammadi S, Mohammadi N, Kazemnejad A. Effect of a breathing exercise on respiratory function and 6-minute walking distance in patients under hemodialysis: a randomized controlled trial. J Nurs Res. 2021;29(2):e146. [
DOI:10.1097/JNR.0000000000000423] [
PMID]
18. Fields DL. Taking the measure of work: A guide to validated scales for organizational research and diagnosis: Sage; 2002. [
DOI:10.4135/9781452231143]
19. Teichman SL, Maisel AS, Storrow AB. Challenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugs. Crit Pathway Cardiol. 2015;14(1):12. [
DOI:10.1097/HPC.0000000000000031] [
PMID] [
]
20. Rich MW. Heart failure disease management programs: efficacy and limitations. Am J Med. 2001;110(5):410-2. [
DOI:10.1016/S0002-9343(01)00632-5] [
PMID]
21. Chen Y, Wang H, Lu Y, Huang X, Liao Y, Bin J. Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials. BMC Med. 2015;13(1):1-12. [
DOI:10.1186/s12916-014-0261-8] [
PMID] [
]
22. Vizzardi E, D'Aloia A, Giubbini R, et al. Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure. Am J Cardiol. 2010;106(9):1292-6. [
DOI:10.1016/j.amjcard.2010.06.052] [
PMID]
23. Inampudi C, Parvataneni S, Morgan CJ, et al. Spironolactone use and higher hospital readmission for Medicare beneficiaries with heart failure, left ventricular ejection fraction< 45%, and estimated glomerular filtration rate< 45 ml/min/1.73 m2. Am J Cardiol. 2014;114(1):79-82. [
DOI:10.1016/j.amjcard.2014.03.062] [
PMID] [
]
24. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New Engl J Med. 1999;341(10):709-17. [
DOI:10.1056/NEJM199909023411001] [
PMID]
25. Hoyt RE, Bowling LS. Reducing readmissions for congestive heart failure. Am Family Physic. 2001;63(8):1593-9.
26. Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Europ Heart J. 2014;35(7):455-69. [
DOI:10.1093/eurheartj/eht386] [
PMID]
27. Stubnova V, Os I, Grundtvig M, Atar D, Waldum-Grevbo B. Spironolactone treatment and effect on survival in chronic heart failure patients with reduced renal function: A propensity-matched study. Cardioren Med. 2017;7(2):128-36. [
DOI:10.1159/000454933] [
PMID] [
]